LTRN Lantern Pharma Inc.

CIK 0001763950 21 ready 8-Ks latest May 15, 2026, 4:07 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline

Ready 8-Ks 21

Latest filing June 1, 2026, 7:40 PM ET

Top materiality 0.75

Event mix earnings ×11 · other_material ×7 · leadership ×2

Sentiment 4 pos · 0 neg · 17 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for LTRN

Highest-materiality recent filing

Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer

May 15, 2026, 4:07 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.

Read filing →

May 15, 2026, 4:07 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer

Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
May 14, 2026, 5:26 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 8.01 item 9.01

Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform

Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
March 30, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances

Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
November 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate

Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
August 13, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials

Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025

Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances

Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in

Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR

Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
March 18, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance

Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.

Earnings & guidance

2026-Q1 EPS reported -$0.30 filing →

Materiality & sentiment trend

Max materiality 0.75 · Median 0.55 · Most common event earnings

4 positive 0 negative 17 neutral

source · LTRN on sec.gov